Cellectis: Monthly Information on Share Capital and Company Voting Rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS--()--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS):

Listing market: NYSE Euronext Paris

ISIN code: FR0010425595

                     
  Date      

Total number of shares
in the capital

      Total number of voting rights  
  05/31/2017       35,385,060       40,663,086  
             

About Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

# # #

Contacts

For further information, please contact:
Media contacts:
Jennifer Moore, VP of Communications
917-580-1088
media@cellectis.com
or
Caitlin Kasunich, KCSA Strategic Communications
212-896-1241
ckasunich@kcsa.com
or
IR contact:
Simon Harnest, VP of Corporate Strategy and Finance
646-385-9008
simon.harnest@cellectis.com

Release Summary

Monthly information on share capital and company voting rights

Contacts

For further information, please contact:
Media contacts:
Jennifer Moore, VP of Communications
917-580-1088
media@cellectis.com
or
Caitlin Kasunich, KCSA Strategic Communications
212-896-1241
ckasunich@kcsa.com
or
IR contact:
Simon Harnest, VP of Corporate Strategy and Finance
646-385-9008
simon.harnest@cellectis.com